May 1, 2014 / 11:12 AM / in 4 years

Shire raises outlook after Q1 earnings beat

LONDON, May 1 (Reuters) - Shire, a pharmaceutical group created by acquisition, soundly beat expectations with a 38 percent rise in first-quarter earnings, underlining its own appeal as a target in the latest wave of deal making in the sector.

Shire, which has franchises in drugs to treat hyperactivity and rare diseases, reported earnings per share-ADS of $2.36, its preferred measure, on revenue of $1.35 billion, boosted by strong sales across its portfolio.

The group raised its outlook for earnings growth this year to mid-to-high 20 percent growth from its previous prediction of similar growth to the 23 percent it recorded in 2013.

Allergan Inc, the botox maker, is preparing a takeover approach for Dublin-based Shire, Reuters reported on Tuesday.

Shire, which has a market capitalization of $33 billion, has long outpaced its big pharma rivals growing revenues and profits. Its base in Dublin, which has a lower rate of corporation tax than many countries including the United States, adds to its appeal.

Analysts expected Shire to post revenue of $1.38 billion and non-GAAP earnings per ADS of $2.22, according to a company compiled poll of 19 brokers.

Reporting by Paul Sandle; editing by Kate Holton

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below